Selected article for: "acute respiratory syndrome and administration remdesivir"
Author: Zhand, Sareh; Saghaeian Jazi, Marie; Mohammadi, Saeed; Tarighati Rasekhi, Roozbeh; Rostamian, Ghassem; Kalani, Mohammad Reza; Rostamian, Aida; George, Jacob; Douglas, Mark W
Title: COVID-19: The Immune Responses and Clinical Therapy Candidates
  • Cord-id: kaglnlok
  • Document date: 2020_8_3
    • ID: kaglnlok
    Snippet: The pandemic of coronavirus disease 2019 (COVID-19), with rising numbers of patients worldwide, presents an urgent need for effective treatments. To date, there are no therapies or vaccines that are proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several potential candidates or repurposed drugs are under investigation, including drugs that inhibit SARS-CoV-2 replication and block infection. The most promising therapy to date is remdesivir, which is US
    Document: The pandemic of coronavirus disease 2019 (COVID-19), with rising numbers of patients worldwide, presents an urgent need for effective treatments. To date, there are no therapies or vaccines that are proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several potential candidates or repurposed drugs are under investigation, including drugs that inhibit SARS-CoV-2 replication and block infection. The most promising therapy to date is remdesivir, which is US Food and Drug Administration (FDA) approved for emergency use in adults and children hospitalized with severe suspected or laboratory-confirmed COVID-19. Herein we summarize the general features of SARS-CoV-2’s molecular and immune pathogenesis and discuss available pharmacological strategies, based on our present understanding of SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) infections. Finally, we outline clinical trials currently in progress to investigate the efficacy of potential therapies for COVID-19.

    Search related documents:
    Co phrase search for related documents
    • abdominal discomfort and liver failure: 1
    • aberrant activation and activation result: 1, 2, 3, 4
    • aberrant activation and acute inflammation: 1
    • aberrant activation and acute respiratory distress syndrome: 1, 2
    • aberrant activation and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • aberrant activation and adaptive immune response: 1, 2, 3, 4
    • aberrant activation and lung disease: 1, 2, 3
    • aberrant activation and lung inflammation: 1
    • aberrant activation and lung tissue: 1, 2, 3, 4
    • accessory protein and action mechanism: 1